Pharmaco-Technological Characterization, Structural Analysis, and Toxicological Evaluation of the Novel Polyene Antibiotic Roseofungin for Drug Development.
Article in Pharmaceutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
14 authors.
Amankeldy SadanovScientific Production Center for Microbiology and Virology LLP, Almaty 050010, Kazakhstan.
Dmitriy BerilloDepartment of Chemistry, M. Kozybayev North-Kazakhstan University, Zhumabaeva Str., 114, Petropavlovsk 150000, Kazakhstan.ORCID 0000-0003-2534-9367
Assya BagimbayevaScientific Production Center for Microbiology and Virology LLP, Almaty 050010, Kazakhstan.
Gul BaimakhanovaScientific Production Center for Microbiology and Virology LLP, Almaty 050010, Kazakhstan.ORCID 0000-0001-5416-3209
Liliya N IbragimovaCenter for Pharmacy and Pharmacology of the Science and Technology Park, JSC Asfendiyarov Kazakh National Medical University, Almaty 050012, Kazakhstan.ORCID 0000-0002-8381-5330
Iliyas Raikhanovich KulmaganbetovScientific Production Center for Microbiology and Virology LLP, Almaty 050010, Kazakhstan.
Farida NurmaganbetovaScientific Production Center for Microbiology and Virology LLP, Almaty 050010, Kazakhstan.
Gulbany SarsenbaevaScientific Production Center for Microbiology and Virology LLP, Almaty 050010, Kazakhstan.ORCID 0000-0002-1310-3936
Saltanat OrazymbetScientific Production Center for Microbiology and Virology LLP, Almaty 050010, Kazakhstan.
Baiken BaimakhanovaScientific Production Center for Microbiology and Virology LLP, Almaty 050010, Kazakhstan.ORCID 0000-0002-7119-950X
Olga LakhScientific Production Center for Microbiology and Virology LLP, Almaty 050010, Kazakhstan.
Diana TleubekovaScientific Production Center for Microbiology and Virology LLP, Almaty 050010, Kazakhstan.
Gulnara T DzhakibaevaScientific Production Center for Microbiology and Virology LLP, Almaty 050010, Kazakhstan.
Tulegen MussaldinovScientific Production Center for Microbiology and Virology LLP, Almaty 050010, Kazakhstan.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Pharmaco-Technological Characterization, Structural Analysis, and Toxicological Evaluation of the Novel Polyene Antibiotic Roseofungin for Drug Development. · full record | OpenQuestion